Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

AMAG Pharmaceuticals Inc (NASDAQ:AMAG)

23.00
Delayed Data
As of Jan 13
 +0.50 / +2.22%
Today’s Change
17.92
Today|||52-Week Range
36.83
-33.91%
Year-to-Date
AMAG, Palatin Ink Deal to Focus on Female Sexual Disorder
Jan 10 / Zacks.com - Paid Partner Content
New Strong Sell Stocks for January 9th
Jan 09 / Zacks.com - Paid Partner Content
Why AMAG Pharmaceuticals, Inc. Is Falling Today
Jan 09 / MotleyFool.com - Paid Partner Content
Trump threat fails to halt drug price hikes in 2017
Jan 04 / CNNMoney.com

Today’s Trading

Previous close22.50
Today’s open22.60
Day’s range22.60 - 23.30
Volume1,186,727
Average volume (3 months)1,033,329
Market cap$786.8M
Dividend yield--
Data as of 4:00pm ET, 01/13/2017

Growth & Valuation

Earnings growth (last year)-82.73%
Earnings growth (this year)+545.43%
Earnings growth (next 5 years)+0.02%
Revenue growth (last year)+236.28%
P/E ratio53.5
Price/Sales2.55
Price/Book0.86

Competitors

 Today’s
change
Today’s
% change
RTRXRetrophin Inc+0.32+1.67%
CRSPCRISPR Therapeutics ...-1.09-4.90%
MYOVMyovant Sciences Ltd0.000.00%
ANIPANI Pharmaceuticals ...-0.02-0.03%
Data as of 4:00pm ET, 01/13/2017

Financials

Next reporting dateMarch 3, 2017
EPS forecast (this quarter)$1.88
Annual revenue (last year)$418.3M
Annual profit (last year)$32.8M
Net profit margin7.84%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
William K. Heiden
President &
Chief Operating Officer
Frank E. Thomas
Corporate headquarters
Waltham, Massachusetts

Forecasts


Search for Jobs